BRAF and melanoma: To avoid systemic side effects, targeted therapy was introduced where BRAF inhibitors (e.g., vemurafenib), MEK inhibitors (e.g., trametinib) and c-KIT inhibitors specifically target the affected mutated melanoma cells [16,17].